Lesson plan
SR9011
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC 50 ) = 790 nM for Rev-Erbα and IC 50 = 560 nM for Rev-ErbAβ. It has been used in the study of the regulation of the circadian rhythm and its links to immune system function, inflammation and cancer.
Article summary
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC 50 ) = 790 nM for Rev-Erbα and IC 50 = 560 nM for Rev-ErbAβ. It has been used in the study of the regulation of the circadian rhythm and its links to immune system function, inflammation and cancer.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.